Immune Checkpoint Inhibitors and Lupus Erythematosus
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number of malignancies. Unfortunately, they are associated with a broad range of unique toxicities that mimic the presentations of primary autoimmune conditions. These adverse events are termed immune-related adverse events (...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-02-01
|
| Col·lecció: | Pharmaceuticals |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1424-8247/17/2/252 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|